Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning.
Marie RobinKavita RajSylvie ChevretJordan GauthierHugues de LavalladeDavid MichonneauDonal McLornanRégis Peffault de LatourVictoria PotterAustin KulasekararajFlore Sicre de FontbruneAntonio PagliucaIbrahim Yakoub-AghaGérard SociéGhulam J MuftiPublished in: European journal of haematology (2018)
Even if GVHD risk is lowered by alemtuzumab use, it does not translate in better outcome due to higher risk of relapse.